ClinicalTrials.gg
CompletedNCT00897390Updated May 21, 2015Results posted

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

A Phase 1 interventional study of Saxagliptin and Metformin IR (glucophage) in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
59th of 74
24 · median 138
Started
2009
with 9 others
Phase 1
14 of 74
none open now
Registered
15th of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 59th largest by enrollment, is one of 10 that started in 2009, is one of 14 in phase 1, and was the 15th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To demonstrate bioequivalence of a 2.5 mg saxagliptin/1000 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 1000 mg metformin IR tablet co-administered to healthy subjects in a fasted and in a fed state.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages 19 to 45 inclusive
  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2

Exclusion criteria

Exclusion Criteria:

  • Women of (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of product
  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds
  • History of allergy or intolerance to metformin or other similar acting agents
  • Prior exposure to saxagliptin
  • Prior exposure to metformin within 3 months of study drug administration
  • Estimated (Clcr) of \< 80ml/min using the Cockcroft Gault formula
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Arm A

    Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions

    Drug: Saxagliptin · Drug: Metformin IR (glucophage)

  • Other
    Arm B

    Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions

    Drug: Saxagliptin + Metformin IR (FDC)

  • Other
    Arm C

    Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal

    Drug: Saxagliptin · Drug: Metformin IR (glucophage)

  • Other
    Arm D

    Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal

    Drug: Saxagliptin + Metformin IR (FDC)

Interventions

  • Tablet, Oral, 2.5 mg, Once Daily, 1 week

    Also known as: Onglyza

  • Tablets, Oral, 1000 mg, Once Daily, 1 week

    Also known as: Glucophage

  • DrugSaxagliptin + Metformin IR (FDC)

    Drug pages: Saxagliptin · Metformin

    Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week

    Also known as: Onglyza, Glucophage

06

What researchers measure

Primary outcomes

  1. Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])

    Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  2. Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])

    Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  3. Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax)

    Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  4. Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF)

    Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  5. Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax)

    Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  6. Metformin PK Parameter AUC(INF)

    Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  7. Metformin PK Parameter AUC(0-T)

    Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  8. Metformin PK Parameter Cmax

    Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  9. Metformin PK Parameter T-HALF

    Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  10. Metformin PK Parameter Tmax

    Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

Secondary outcomes

  1. BMS-510849 PK Parameter AUC(INF)

    Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  2. BMS-510849 PK Parameter AUC(0-T)

    Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  3. BMS-510849 PK Parameter Cmax

    Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  4. BMS-510849 PK Parameter T-Half

    Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from their respective plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  5. BMS-510849 PK Parameter T-Max

    Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

    Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period

  6. Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs

    An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days). SAEs collected from date of written consent until 30 days post discontinuation of dosing or subject's participation in the study.

  7. AEs of Special Interest

    See Outcome Measure 16 for a definition of AEs. AEs of clinical interest for saxagliptin were defined as those relating to the following:skin disorders, infection-related AEs (system organ class \[SOC\]: Infections and Infestations), thrombocytopenia, lymphopenia, hypoglycemia, cardiovascular AEs indicative of acute cardiovascular events, localized edema, fractures, pancreatitis, and AEs of hypersensitivity.

    Time frame: AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days).

  8. Number of Participants With Marked Laboratory Abnormalities (MA)

    Laboratory abnormalities=any result that is clinically significant, met the definition of an SAE, required discontinuation or interruption of study drug, or required specific corrective therapy. Upper normal (UN)/lower normal (LN) values: leukocytes UN, 11.40x10\^3 c/uL; absolute neutrophils/bands LN, 1.500x10\^3 c/uL; aspartate aminotransferase UN, 48 U/L; alanine aminotransferase UN, 67 U/L; blood urea nitrogen UN, 20.0 mg/dL; creatine kinase UN, 350 U/L; lactate dehydrogenase UN, 249 U/L.

    Time frame: Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.

  9. Number of Participants With Marked Urinalysis Abnormalities

    Protein, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Glucose, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Blood, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). White Blood Cell (WBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). Red Blood Cell (RBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). (The '+' is a normal lab result and refers to the magnitude of the finding.)

    Time frame: Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.

  10. Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities

    12-lead Electrocardiogram (ECG), Vital Sign (body temperature, respiratory rate, seated blood pressure and heart rate), and Physical Finding Abnormalities reported by investigator as AEs.

    Time frame: At Screening (within 21 days of Study Day 1), Day -1 of Period 1 (ECG and Physical only), Day 1 of Periods 1-4 (Vitals only), at Study Discharge (Day 3 of Period 4) or Discontinuation

07

Results

Posted Jan 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneAll Treated Participants
Started24
Completed18
Not completed6
Withdrew: Adverse event2
Withdrew: No longer met study criteria1
Withdrew: Personal reasons1
Withdrew: Did not return for the clinic visit2

Outcome measures

PrimarySaxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])

Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])47.25 (30.6 to 66.0)48.91 (28.7 to 80.7)52.89 (37.4 to 75.1)51.11 (34.2 to 73.7)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 1.042 · 90% CI 1.009 to 1.075
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.988 · 90% CI 0.958 to 1.019
SecondaryBMS-510849 PK Parameter AUC(INF)

Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
BMS-510849 PK Parameter AUC(INF)
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
BMS-510849 PK Parameter AUC(INF)118.54 (58.7 to 174.4)116.19 (48.5 to 212.4)127.67 (62.5 to 217.8)127.25 (59.4 to 219.3)
PrimarySaxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])

Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])44.90 (29.1 to 64.3)46.57 (27.8 to 77.7)50.50 (35.6 to 73.2)49.09 (33.5 to 71.3)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 1.045 · 90% CI 1.013 to 1.077
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.992 · 90% CI 0.962 to 1.022
PrimarySaxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax)

Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng/mL
Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax)
ng/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax)8.58 (5.2 to 15.5)9.09 (5.5 to 17.1)10.97 (7.6 to 18.2)10.80 (7.4 to 15.9)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 1.077 · 90% CI 0.978 to 1.185
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.987 · 90% CI 0.900 to 1.083
PrimarySaxagliptin PK Parameter Plasma Terminal Half-life (T-HALF)

Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Mean · hours
Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF)
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF)6.66 ± 1.1856.34 ± 0.9416.47 ± 1.5295.78 ± 1.333
PrimarySaxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax)

Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Median · hours
Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax)
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax)1.50 (0.5 to 4.0)0.75 (0.3 to 3.0)1.00 (0.3 to 3.0)1.50 (0.3 to 3.0)
PrimaryMetformin PK Parameter AUC(INF)

Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
Metformin PK Parameter AUC(INF)
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Metformin PK Parameter AUC(INF)13363.46 (8872.9 to 19164.2)12677.92 (8827.3 to 16811.6)12357.87 (6875.3 to 15926.2)12126.19 (7328.6 to 15424.7)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 0.974 · 90% CI 0.921 to 1.030
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.966 · 90% CI 0.915 to 1.020
PrimaryMetformin PK Parameter AUC(0-T)

Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
Metformin PK Parameter AUC(0-T)
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Metformin PK Parameter AUC(0-T)13238.43 (8782.0 to 18991.8)12400.41 (8105.3 to 16603.8)12124.31 (6629.2 to 15842.4)11996.88 (7142.5 to 15326.6)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 0.962 · 90% CI 0.906 to 1.020
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.974 · 90% CI 0.920 to 1.032
PrimaryMetformin PK Parameter Cmax

Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng/mL
Metformin PK Parameter Cmax
ng/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Metformin PK Parameter Cmax2004.99 (1187.2 to 3144.6)1830.76 (1142.5 to 2662.5)1666.55 (768.7 to 2256.5)1642.90 (848.1 to 2018.3)
Statistical analysis
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted vs FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted · Adjusted geometric mean: 0.937 · 90% CI 0.864 to 1.016
  • 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed vs FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed · Adjusted geometric mean: 0.964 · 90% CI 0.891 to 1.042
PrimaryMetformin PK Parameter T-HALF

Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Mean · hours
Metformin PK Parameter T-HALF
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Metformin PK Parameter T-HALF8.43 ± 2.95610.58 ± 8.89511.78 ± 5.9997.63 ± 2.309
PrimaryMetformin PK Parameter Tmax

Single-dose PK parameters of metformin were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Median · hours
Metformin PK Parameter Tmax
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Metformin PK Parameter Tmax2.00 (1.0 to 4.0)2.98 (1.5 to 4.0)4.00 (2.0 to 4.0)4.00 (3.0 to 4.0)
SecondaryBMS-510849 PK Parameter AUC(0-T)

Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng*h/mL
BMS-510849 PK Parameter AUC(0-T)
ng*h/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
BMS-510849 PK Parameter AUC(0-T)108.31 (52.0 to 169.2)106.11 (42.3 to 201.4)117.42 (54.3 to 210.7)117.43 (51.1 to 210.9)
SecondaryBMS-510849 PK Parameter Cmax

Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Geometric mean · ng/mL
BMS-510849 PK Parameter Cmax
ng/mL2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
BMS-510849 PK Parameter Cmax16.77 (6.4 to 32.8)15.17 (4.7 to 32.0)18.24 (7.6 to 36.5)18.58 (6.2 to 33.5)
SecondaryBMS-510849 PK Parameter T-Half

Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from their respective plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Mean · hours
BMS-510849 PK Parameter T-Half
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
BMS-510849 PK Parameter T-Half8.05 ± 1.4277.31 ± 1.3697.48 ± 1.5047.35 ± 1.622
SecondaryBMS-510849 PK Parameter T-Max

Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.

Time frame:
pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Reported as:
Median · hours
BMS-510849 PK Parameter T-Max
hours2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
BMS-510849 PK Parameter T-Max2.00 (1.0 to 4.0)2.00 (0.8 to 4.0)2.00 (1.0 to 4.0)2.00 (1.0 to 4.0)
SecondaryDeaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs

An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days). SAEs collected from date of written consent until 30 days post discontinuation of dosing or subject's participation in the study.
Reported as:
Number · participants
Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs
participants2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Deaths0000
SAEs0000
AEs5243
Discontinuations dues to AEs0011
SecondaryAEs of Special Interest

See Outcome Measure 16 for a definition of AEs. AEs of clinical interest for saxagliptin were defined as those relating to the following:skin disorders, infection-related AEs (system organ class \[SOC\]: Infections and Infestations), thrombocytopenia, lymphopenia, hypoglycemia, cardiovascular AEs indicative of acute cardiovascular events, localized edema, fractures, pancreatitis, and AEs of hypersensitivity.

Time frame:
AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days).
Reported as:
Number · participants
AEs of Special Interest
participants2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
AEs of Special Interest0000
SecondaryNumber of Participants With Marked Laboratory Abnormalities (MA)

Laboratory abnormalities=any result that is clinically significant, met the definition of an SAE, required discontinuation or interruption of study drug, or required specific corrective therapy. Upper normal (UN)/lower normal (LN) values: leukocytes UN, 11.40x10\^3 c/uL; absolute neutrophils/bands LN, 1.500x10\^3 c/uL; aspartate aminotransferase UN, 48 U/L; alanine aminotransferase UN, 67 U/L; blood urea nitrogen UN, 20.0 mg/dL; creatine kinase UN, 350 U/L; lactate dehydrogenase UN, 249 U/L.

Time frame:
Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.
Reported as:
Number · participants
Number of Participants With Marked Laboratory Abnormalities (MA)
participants2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Leukocytes - High(>1.2 * upper limit normal [ULN])0001
Abs. Neutrophils/Bands-Low (<=lower LN [LLN])1111
Aspartate Aminotransferase - High (>1.25 * ULN)0001
Alanine Aminotransferase - High (>1.25 * ULN)0001
Blood Urea Nitrogen - High (1.1 * ULN)0110
Creatine Kinase - High (>1.5 ULN)1102
Lactate Dehydrogenase - High (>1.25 ULN)0001
SecondaryNumber of Participants With Marked Urinalysis Abnormalities

Protein, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Glucose, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Blood, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). White Blood Cell (WBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). Red Blood Cell (RBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). (The '+' is a normal lab result and refers to the magnitude of the finding.)

Time frame:
Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.
Reported as:
Number · participants
Number of Participants With Marked Urinalysis Abnormalities
participants2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
Protein, Urine (n=19, 19, 20, 21)0000
Glucose, Urine (n=19, 19, 20, 21)0000
Blood, Urine (n=19, 19, 20, 21)1002
White Blood Cells, Urine (n=2, 2, 2, 2)0010
Red Blood Cells, Urine (n=2, 2, 2, 2)0000
SecondaryElectrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities

12-lead Electrocardiogram (ECG), Vital Sign (body temperature, respiratory rate, seated blood pressure and heart rate), and Physical Finding Abnormalities reported by investigator as AEs.

Time frame:
At Screening (within 21 days of Study Day 1), Day -1 of Period 1 (ECG and Physical only), Day 1 of Periods 1-4 (Vitals only), at Study Discharge (Day 3 of Period 4) or Discontinuation
Reported as:
Number · participants
Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities
participants2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed
ECG Abnormalities0000
Vital Sign Abnormalities0000
Physical Finding Abnormalities0000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted—0/19 (0%)3/19 (15.8%)
FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted—0/19 (0%)2/19 (10.5%)
2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed—0/21 (0%)2/21 (9.5%)
FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed—0/24 (0%)3/24 (12.5%)
Not Dosed—0/34 (0%)0/34 (0%)
Most frequent other events
Showing 10 of 25
Most frequent other events
Event2.5-mg Saxa Tablet/1000-mg Met Tablet, FastedFDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted2.5-mg Saxa Tablet/1000-mg Met Tablet, FedFDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, FedNot Dosed
HEADACHENervous system disorders1/62/62/61/60/34
DIARRHOEAGastrointestinal disorders0/60/61/62/60/34
EYE DISCHARGEEye disorders0/60/61/60/60/34
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/60/60/60/60/34
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/60/60/60/60/34
BLOOD LACTATE DEHYDROGENASE INCREASEDInvestigations1/60/60/60/60/34
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations1/60/60/60/60/34
PALPITATIONSCardiac disorders0/61/60/60/60/34
DIZZINESSNervous system disorders0/61/60/60/60/34
NAUSEAGastrointestinal disorders1/60/61/60/60/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled and Treated Participants
Mean30 ± 6
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled and Treated Participants
Female8
Male16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Enrolled and Treated Participants
White20
Black4
Body Mass Index
Body Mass Index(kg/m^2)All Enrolled and Treated Participants
Mean26.5 ± 3.8
weight
weight(kg)All Enrolled and Treated Participants
Mean79.9 ± 15.0
08

Study locations

1 site
  • Mds Pharma Services
    Lincoln, Nebraska 68502, United States
09

References and documents

Publications

  • Upreti VV, Keung CF, Boulton DW, Chang M, Li L, Tang A, Hsiang BC, Quamina-Edghill D, Frevert EU, Lacreta FP. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects. Clin Drug Investig. 2013 May;33(5):365-74. doi: 10.1007/s40261-013-0075-z. PubMed 23549864 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2009
First posted
May 12, 2009
Start
Jun 2009
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Jan 21, 2011
Last update
May 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00897390
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 12, 2009
Start date
Jun 2009
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Jan 21, 2011
Last update
May 21, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Metformin

Start the discussion